Citi: Maintains TIGERMED Outperform Rating, Moderate Recovery in Q3
I'm PortAI, I can summarize articles.
Citi released a research report stating that Tigermed's third-quarter performance reflects a moderate recovery in the company's business. Although profit margins remain under pressure, it is expected that products may rebound in 2026. The revenue forecasts for 2025 to 2027 are largely maintained, while net profit forecasts are adjusted up by 28.9%, down by 14.6%, and down by 14.1%, respectively, to reflect the profit margin outlook. The target price is lowered from HKD 58.9 to HKD 52.1, while maintaining an "outperform" rating
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments